Drug class · Oncology & immunology
Kinase inhibitors Drug Codes & NDCs
Small-molecule drugs that inhibit one or more protein kinases. Most are oral products dispensed by pharmacies.
FDA-listed products
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Sunitinib Malate | Sunitinib malate 50 mg/1 | CapsuleOral | Novugen Pharma (USA) LLC. | 82293-017 |
| Sutentsunitinib malate | Sunitinib malate 12.5 mg/1 | CapsuleOral | Pfizer Laboratories Div Pfizer Inc | 0069-0550 |
| Sutentsunitinib malate | Sunitinib malate 25 mg/1 | CapsuleOral | Pfizer Laboratories Div Pfizer Inc | 0069-0770 |
| Sutentsunitinib malate | Sunitinib malate 37.5 mg/1 | CapsuleOral | Pfizer Laboratories Div Pfizer Inc | 0069-0830 |
| Sutentsunitinib malate | Sunitinib malate 50 mg/1 | CapsuleOral | Pfizer Laboratories Div Pfizer Inc | 0069-0980 |
| Tabrectacapmatinib | Capmatinib hydrochloride 150 mg/1 | Tablet, Film coatedOral | Novartis Pharmaceuticals Corporation | 0078-0709 |
| Tabrectacapmatinib | Capmatinib hydrochloride 200 mg/1 | Tablet, Film coatedOral | Novartis Pharmaceuticals Corporation | 0078-0716 |
| Tafinlardabrafenib | Dabrafenib mesylate 75 mg/1 | CapsuleOral | Novartis Pharmaceuticals Corporation | 0078-0681 |
| Tafinlardabrafenib | Dabrafenib mesylate 50 mg/1 | CapsuleOral | Novartis Pharmaceuticals Corporation | 0078-0682 |
| Tafinlardabrafenib | Dabrafenib mesylate 10 mg/1 | Tablet, For suspensionOral | Novartis Pharmaceuticals Corporation | 0078-1154 |
| Tagrissoosimertinib | Osimertinib 40 mg/1 | Tablet, Film coatedOral | AstraZeneca Pharmaceuticals LP | 0310-1248 |
| Tagrissoosimertinib | Osimertinib 80 mg/1 | Tablet, Film coatedOral | AstraZeneca Pharmaceuticals LP | 0310-1251 |
| Tagrissoosimertinib | Osimertinib 40 mg/1 | Tablet, Film coatedOral | AstraZeneca Pharmaceuticals LP | 0310-1349 |
| Tagrissoosimertinib | Osimertinib 80 mg/1 | Tablet, Film coatedOral | AstraZeneca Pharmaceuticals LP | 0310-1350 |
| Tasignanilotinib | Nilotinib hydrochloride monohydrate 200 mg/1 | CapsuleOral | Novartis Pharmaceuticals Corporation | 0078-0526 |
| Tasignanilotinib | Nilotinib hydrochloride monohydrate 150 mg/1 | CapsuleOral | Novartis Pharmaceuticals Corporation | 0078-0592 |
| Tasignanilotinib | Nilotinib hydrochloride monohydrate 50 mg/1 | CapsuleOral | Novartis Pharmaceuticals Corporation | 0078-0951 |
| Tepmetkotepotinib hydrochloride | Tepotinib hydrochloride 225 mg/1 | TabletOral | EMD Serono, Inc. | 44087-5000 |
| Tofacitinib | Tofacitinib citrate 11 mg/1 | Tablet, Extended releaseOral | Ajanta Pharma USA Inc. | 27241-270 |
| Tofacitinib | Tofacitinib citrate 5 mg/1 | Tablet, Film coatedOral | Macleods Pharmaceuticals Limited | 33342-541 |
| Tofacitinib | Tofacitinib citrate 10 mg/1 | Tablet, Film coatedOral | Macleods Pharmaceuticals Limited | 33342-542 |
| Tofacitinib | Tofacitinib citrate 5 mg/1 | Tablet, Film coatedOral | Micro Labs Limited | 42571-268 |
| Tofacitinib | Tofacitinib citrate 10 mg/1 | Tablet, Film coatedOral | Micro Labs Limited | 42571-377 |
| Tofacitinib | Tofacitinib citrate 11 mg/1 | Tablet, Film coated, Extended releaseOral | Edenbridge Pharmaceuticals LLC. | 42799-970 |
| Tofacitinibtofacitinib citrate | Tofacitinib citrate 5 mg/1 | TabletOral | Breckenridge Pharmaceutical, Inc. | 51991-329 |